Abstract

Secretion of renin juxtaglomerular cells into bloodstream initiates activation of an enzymatic-hormonal cascade known as the RAAS (renin – angiotensin – aldosterone system). As a result, blood pressure is increased by the means several interrelated mechanisms. Mechanism of Zjednoczoaction of this system has been known for decades, but a few previously unknown components were recently added, such as ACE-2 and Ang(1-7), and their role often seems to be opposite to that of the conventional components. Local tissue systems also have important biological functions. They operate largely independently of the systemic activity, and their activity is observed primarily in the kidney, heart, in blood vessels, adrenal gland and nervous system. Angiotensin-2 (Ang-2), the main RAAS effector, has a wide scope of action, and thus abnormalities in its functioning have many consequences. Excessive activation is accompanied by chronic inflammation, as Ang-2 stimulates inflammatory mediators. As a result, degenerative processes and atherosclerosis are initiated. RAAS imbalance is associated with the most common diseases of civilization, such as cardio-vascular diseases, diabetes, kidney diseases, preeclampsia, osteoporosis and even neurodegenerative diseases. Many of these pathological processes are attributed to the excessive activation of tissue RA system. Therapeutic strategies based on inhibition of the RAAS are commonly used mainly in the treatment of hypertension and other cardiovascular disorders. The benefits of this class of drugs is primarily a decrease in blood pressure, but also the suppression of inflammatory processes and other pathological phenomena resulting from excessive activation of the RAAS. For that reason, some consider to use RAAS inhibitors in other diseases, e.g. Parkinson’s disease. Further studies give hope for the improvement of RAAS inhibitor therapy and the development of new therapeutic strategies

References

• 1. Andrésdóttir G., Jensen M.L., Carstensen B., Parving H.H., RossingK., Hansen T.W., Rossing P.: Improved survival and renal prognosisof patients with type 2 diabetes and nephropathy with improvedcontrol of risk factors. Diabetes Care, 2014; 37: 1660-1667
  Google Scholar
• 2. Aroor A.R., Demarco V.G., Jia G., Sun Z., Nistala R., MeiningerG.A., Sowers J.R.: The role of tissue renin-angiotensin-aldosteronesystem in the development of endothelial dysfunction and arterialstiffness. Front Endocrinol., 2013; 4: 161
  Google Scholar
• 3. Asaba Y., Ito M., Fumoto T., Watanabe K., Fukuhara R., TakeshitaS., Nimura Y., Ishida J., Fukamizu A., Ikeda K.: Activation of reninangiotensinsystem induces osteoporosis independently of hypertension.J. Bone Miner. Res., 2009; 24: 241-250
  Google Scholar
• 4. Atlas S.A.: The renin-angiotensin aldosterone system: pathophysiologicalrole and pharmacologic inhibition. J. Manag. CarePharm., 2007; 13 (Suppl. S-b): S9-S20
  Google Scholar
• 5. Boden W.E., O’Rourke R.A., Teo K.K., Hartigan P.M., Maron D.J.,Kostuk W.J., Knudtson M., Dada M., Casperson P., Harris C.L., ChaitmanB.R., Shaw L., Gosselin G., Nawaz S., Title L.M. i wsp.: Optimalmedical therapy with or without PCI for stable coronary disease. N.Engl. J. Med., 2007; 356: 1503-1516
  Google Scholar
• 6. Brooks M.: Top 100 most prescribed, top-selling drugs. MedscapeMedical N. http://www.medscape.com/viewarticle/829246(01.08.2014)
  Google Scholar
• 7. Brown M.J.: Direct renin inhibition — a new way of targetingthe renin system. J. Renin Angiotensin Aldosterone Syst., 2006; 7(Suppl. 1): S7-S11
  Google Scholar
• 8. Carey R.M., Siragy H.M.: Newly recognized components of therenin-angiotensin system: potential roles in cardiovascular and renalregulation. Endocr. Rev., 2003; 24: 261-271
  Google Scholar
• 9. Danser A.H., van Kats J.P, Admiraal P.J., Derkx F.H., Lamers J.M.,Verdouw P.D., Saxena P.R., Schalekamp M.A.: Cardiac renin and angiotensins.Uptake from plasma versus in situ synthesis. Hypertension,1994; 24: 37-48
  Google Scholar
• 10. De Mello W.C., Danser A.H.: Angiotensin II and the heart: onthe intracrine renin-angiotensin system. Hypertension, 2000; 35:1183-1188
  Google Scholar
• 11. Doughan A.K., Harrison D.G., Dikalov S.I.: Molecular mechanismsof angiotensin II-mediated mitochondrial dysfunction: linking mitochondrialoxidative damage and vascular endothelial dysfunction.Circ. Res., 2008; 102: 488-496
  Google Scholar
• 12. Dronavalli S., Duka I., Bakris G.L.: The pathogenesis of diabeticnephropathy. Nat. Clin. Pract. Endocrinol. Metab., 2008; 4: 444-452
  Google Scholar
• 13. Dzau V., Braunwald E.: Resolved and unresolved issues in theprevention and treatment of coronary artery disease: a workshopconsensus statement. Am. Heart J., 1991; 121: 1244-1263
  Google Scholar
• 14. Dzau V.J., Antman E.M., Black H.R., Hayes D.L., Manson J.E., PlutzkyJ., Popma J.J., Stevenson W.: The cardiovascular disease continuumvalidated: clinical evidence of improved patient outcomes: part I:Pathophysiology and clinical trial evidence (risk factors throughstable coronary artery disease). Circulation, 2006; 114: 2850-2870
  Google Scholar
• 15. Ferrari R.: Cardiovascular protection: a breakthrough for highriskpatients? J. Hypertens. Suppl., 2009; 27: S37-S40
  Google Scholar
• 16. Ferrario C.M., Strawn W.B.: Role of the renin-angiotensin-aldosteronesystem and proinflammatory mediators in cardiovasculardisease. Am. J. Cardiol., 2006; 98: 121-128
  Google Scholar
• 17. Głuszek J., Kosicka T.: Czy nadciśnienie tętnicze jest przewlekłąchorobą zapalną? Nadciśnienie Tętnicze, 2011; 15: 363-370
  Google Scholar
• 18. Grzeszczak W.: Nowe dane na temat nefropatii cukrzycowej i nowychkoncepcji terapeutycznych w cukrzycy Czy zbliża się przełomw tym względzie? Choroby Serca i Naczyń, 2011; 8: 183-189
  Google Scholar
• 19. Henriksen E.J., Jacob S.: Modulation of metabolic control byangiotensin converting enzyme (ACE) inhibition. J. Cell. Physiol.,2003; 196: 171-179
  Google Scholar
• 20. Hirata K., Vlachopoulos C., Adji A., O’Rourke M.F.: Benefits fromangiotensin-converting enzyme inhibitor ‚beyond blood pressurelowering’: beyond blood pressure or beyond the brachial artery? J.Hypertens., 2005; 23: 551-556
  Google Scholar
• 21. Kamińska M., Mogielnicki A., Stankiewicz A., Kramkowski K.,Domaniewski T., Buczko W., Chabielska E.: Angiotensin II via AT1 receptoraccelerates arterial thrombosis in renovascular hypertensiverats. J. Physiol. Pharmacol., 2005; 56: 571-585
  Google Scholar
• 22. Kobori H., Nangaku M., Navar L.G., Nishiyama A.: The intrarenalrenin-angiotensin system: from physiology to the pathobiology ofhypertension and kidney disease. Pharmacol. Rev., 2007; 59: 251-287
  Google Scholar
• 23. Kujawa-Szewieczek A., Kocierz M., Piecha G., Kolonko A., ChudekJ., Więcek A.: Polimorfizm genów poszczególnych składowych układurenina-angiotensyna-aldosteron a progresja przewlekłej chorobynerek. Postępy Hig. Med. Dośw., 2010; 64: 423-438
  Google Scholar
• 24. Montecucco F., Pende A., Mach F.: The renin-angiotensin systemmodulates inflammatory processes in atherosclerosis: evidencefrom basic research and clinical studies. Mediat. Inflamm., 2009;2009: 752406
  Google Scholar
• 25. Nishiyama A., Seth D.M., Navar L.G.: Renal interstitial fluid concentrationsof angiotensins I and II in anesthetized rats. Hypertension,2002; 39: 129-134
  Google Scholar
• 26. Obońska K., Grąbczewska Z., Fisz J.: Ocena czynności śródbłonkanaczyniowego — gdzie jesteśmy, dokąd zmierzamy? Fol. Cardiol.Exc., 2010; 5: 292-297 27 Pacurari M., Kafoury R., Tchounwou P.B., Ndebele K.: The reninangiotensin-aldosteronesystem in vascular inflammation and remodeling.Int. J. Inflam., 2014; 2014: 689360
  Google Scholar
• 27. (Suppl. 3): iii51-iii57
  Google Scholar
• 28. Padwal R., Straus S.E., McAlister F.A.: Evidence based managementof hypertension. Cardiovascular risk factors and their effectson the decision to treat hypertension: evidence based review. BMJ,2001; 322: 977-980
  Google Scholar
• 29. Patel B.M., Mehta A.A.: Aldosterone and angiotensin: role in diabetesand cardiovascular diseases. Eur. J. Pharmacol., 2012; 697: 1-12
  Google Scholar
• 30. Pizoń T., Rajzer M., Kameczura T.: Rola układu renina–angiotensyna–aldosteronw etiologii i patogenezie nadciśnienia tętniczego oraz jego powikłań narządowych – co pozostało z koncepcji Laraghai Aldermana? Nadciśnienie Tętnicze, 2011; 15: 371-382
  Google Scholar
• 31. Proudfoot J.M., Croft K.D., Puddey I.B., Beilin L.J.: AngiotensinII type 1 receptor antagonists inhibit basal as well as low-densitylipoprotein and platelet-activating factor-stimulated human monocytechemoattractant protein-1. J. Pharmacol. Exp. Ther., 2003; 305:846-853
  Google Scholar
• 32. Santos P.C., Krieger J.E., Pereira A.C.: Renin-angiotensin system,hypertension and chronic kidney disease: pharmacogenetic implications.J. Pharmacol. Sci., 2012; 120: 77-88
  Google Scholar
• 33. Santos R.A., Ferreira A.J., Verano-Braga T., Bader M.: Angiotensin-convertingenzyme 2, angiotensin-(1-7) and Mas: new playersof the renin-angiotensin system. J. Endocrinol., 2013; 216: R1-R17
  Google Scholar
• 34. Seki H.: The role of the renin-angiotensin system in the pathogenesisof preeclampsia – new insights into the renin-angiotensinsystem in preeclampsia. Med. Hypotheses, 2014; 82: 362-367
  Google Scholar
• 35. Senchenkova E.Y., Russell J., Esmon C.T., Granger D.N.: Roles ofcoagulation and fibrinolysis in angiotensin II-enhanced microvascularthrombosis. Microcirculation, 2014; 21: 401-407
  Google Scholar
• 36. Shagdarsuren E., Wellner M., Braesen J.H., Park J.K., FiebelerA., Henke N., Dechend R., Gratze P., Luft F.C., Muller D.N.: Complementactivation in angiotensin II-induced organ damage. Circ. Res.,2005; 97: 716-724
  Google Scholar
• 37. Sozen A.B., Kayacan M.S., Tansel T., Celebi A., Kudat H., AkkayaV., Erk O., Hatipoglu I., Demirel S.: Drugs with blocking effects onthe renin-angiotensin-aldosterone system do not improve endothelialdysfunction long-term in hypertensive patients. J. Int. Med.Res., 2009; 37: 996-1002
  Google Scholar
• 38. Steckelings U.M., Rompe F., Kaschina E., Unger T.: The evolvingstory of the RAAS in hypertension, diabetes and CV disease: movingfrom macrovascular to microvascular targets. Fundam. Clin. Pharmacol.,2009; 23: 693-703
  Google Scholar
• 39. Tamura K., Tanaka Y., Tsurumi Y., Azuma K., Shigenaga A., WakuiH., Masuda S., Matsuda M.: The role of angiotensin AT1 receptorassociatedprotein in renin-angiotensin system regulation and function.Curr. Hypertens. Rep., 2007; 9: 121-127
  Google Scholar
• 40. van der Graaf A.M., Toering T.J., Faas M.M., Lely A.T.: From preeclampsiato renal disease: a role of angiogenic factors and the reninangiotensinaldosterone system? Nephrol. Dial. Transplant., 2012;
  Google Scholar
• 41. van Kats J.P., Danser A.H., van Meegen J.R., Sassen L.M., VerdouwP.D., Schalekamp M.A.: Angiotensin production by the heart:a quantitative study in pigs with the use of radiolabeled angiotensininfusions. Circulation, 1998; 98: 73-81
  Google Scholar
• 42. Wassmann S., Czech T., van Eickels M., Fleming I., Bohm M., NickenigG.: Inhibition of diet-induced atherosclerosis and endothelialdysfunction in apolipoprotein E/angiotensin II type 1A receptordouble-knockout mice. Circulation, 2004; 110: 3062-3067
  Google Scholar
• 43. Wenzel R.R.: Renal protection in hypertensive patients: selectionof antihypertensive therapy. Drugs, 2005; 65 (Suppl. 2): 29-39
  Google Scholar
• 44. Wright J.W., Kawas L.H., Harding J.W.: A role for the brainRAS in Alzheimer’s and Parkinson’s diseases. Front. Endocrinol.,2013; 4: 158
  Google Scholar
• 45. Yang J., Shang J., Zhang S., Li H., Liu H.: The role of the reninangiotensin-aldosteronesystem in preeclampsia: genetic polymorphismsand microRNA. J. Mol. Endocrinol., 2013; 50: R53-R66
  Google Scholar
• 46. Zhuo J.L., Ferrao F.M., Zheng Y., Li X.C.: New frontiers in the intrarenalrenin-angiotensin system: a critical review of classical andnew paradigms. Front. Endocrinol., 2013; 4: 166
  Google Scholar

Full text